Figure 2:

Proposed algorithm for the management of patients with primary IgAN. Lifestyle interventions should include advice on dietary sodium restriction (<2 g sodium/day), smoking cessation, weight control and exercise, as appropriate. Assess cardiovascular risk and commence appropriate interventions. Patients should be reviewed regularly (every 4–8 weeks) during optimization of supportive care. For patients with secondary causes of IgAN, treatment should be targeted at the primary disease. Increasing relative risk of treatment-related toxicity for interventions beyond supportive care is indicated by increasing intensity of the background orange colour in the text box. For risk assessment, see also Box ‘Strategies for personalizing treatment in IgAN’. *The safety of co-administrating SGLT2i with immunosuppression is currently unknown.